ABBV - AbbVie Inc.
NEXT EARNINGS:
Apr 24, 2026
EPS Est: $3.01
|
Rev Est: $14.7B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$256.15
DETAILS
HIGH:
$299.00
LOW:
$223.00
MEDIAN:
$258.00
CONSENSUS:
$256.15
UPSIDE:
24.91%
Market Cap:
362.60B
Volume:
27,365,741
Avg Volume:
6,608,520
52 Week Range:
164.39-244.81
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.33
Last Dividend:
$6.65
Exchange:
NYSE
Country:
US
Employees:
55,000
IPO Date:
2013-01-02
EPS (TTM):
2.38
P/E Ratio:
96.82
Revenue (TTM):
61.16B
Total Assets:
133.96B
Total Debt:
69.07B
Cash & Equiv:
5.23B
Rev Growth (5Y):
6.0%
EPS Growth (5Y):
-2.7%
FCF Growth (5Y):
1.2%
ROCE:
10.2%
Debt/Equity:
20.40
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-04 | $2.71 | $2.65 | +2.3% | $16.6B | $16.4B | +1.2% |
| 2025-10-31 | $1.86 | $1.77 | +5.1% | $15.8B | $15.6B | +1.2% |
| 2025-07-31 | $2.97 | $2.88 | +3.1% | $15.4B | $15.0B | +2.6% |
| 2025-04-25 | $2.46 | $2.38 | +3.4% | $13.3B | $12.9B | +3.2% |
| 2025-01-31 | $2.16 | $2.98 | -27.5% | $15.1B | $14.8B | +1.8% |
| 2024-10-30 | $3.00 | $2.92 | +2.7% | $14.5B | $14.3B | +1.2% |
| 2024-07-25 | $2.65 | $2.57 | +3.1% | $14.5B | $14.0B | +3.1% |
| 2024-04-26 | $2.31 | $2.26 | +2.2% | $12.3B | $11.9B | +3.2% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 61.16B | 56.33B | 54.32B | 58.05B | 56.20B | 45.80B | 33.27B | 32.75B | 28.22B | 25.64B | 22.86B | 19.96B |
| Net Income | 4.23B | 4.28B | 4.86B | 11.84B | 11.54B | 4.62B | 7.88B | 5.69B | 5.31B | 5.95B | 5.14B | 1.77B |
| EPS | 2.38 | 2.40 | 2.73 | 6.65 | 6.48 | 2.73 | 5.30 | 3.69 | 3.31 | 3.65 | 3.15 | 1.11 |
| Total Assets | 133.96B | 135.16B | 134.71B | 138.81B | 146.53B | 150.56B | 89.11B | 59.35B | 70.79B | 66.10B | 53.05B | 27.51B |
| Total Debt | 69.07B | 67.84B | 60.12B | 64.19B | 77.58B | 87.06B | 67.09B | 40.31B | 37.37B | 36.84B | 31.67B | 15.01B |
| Cash & Equivalents | 5.23B | 5.52B | 12.81B | 9.20B | 9.75B | 8.45B | 39.92B | 7.29B | 9.30B | 5.10B | 8.40B | 8.35B |
| Operating Cash Flow | 19.03B | 18.81B | 22.84B | 24.94B | 22.78B | 17.59B | 13.32B | 13.43B | 9.96B | 7.04B | 7.54B | 3.55B |
| Free Cash Flow | 17.82B | 17.83B | 22.06B | 24.25B | 21.99B | 16.79B | 12.77B | 12.79B | 9.43B | 6.56B | 7.00B | 2.94B |
| FCF per Share | 9.95 | 10.08 | 12.48 | 13.69 | 12.42 | 10.07 | 8.62 | 8.30 | 5.91 | 4.05 | 4.31 | 1.84 |
| Book Value | (3.27B) | 3.33B | 10.36B | 17.25B | 15.41B | 13.08B | (8.17B) | (8.45B) | 5.10B | 4.64B | 3.94B | 1.74B |
| Cash & ST Investments | 5.26B | 5.55B | 12.82B | 9.23B | 9.83B | 8.48B | 39.92B | 8.06B | 9.79B | 6.42B | 8.41B | 8.37B |
| ROC Equity | N/A | 1.29 | 0.47 | 0.69 | 0.75 | 0.35 | N/A | N/A | 1.04 | 1.28 | 1.30 | 1.02 |